SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
0.888
-0.010 (-1.11%)
At close: Dec 20, 2024, 4:00 PM
0.950
+0.062 (6.98%)
After-hours: Dec 20, 2024, 7:47 PM EST
SLS Employees
SELLAS Life Sciences Group had 16 employees as of December 31, 2023. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
n/a
Profits / Employee
-$2,017,500
Market Cap
62.50M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
111, Inc. | 1,520 |
Burning Rock Biotech | 786 |
InterCure | 270 |
OptiNose | 132 |
IceCure Medical | 77 |
Vistagen Therapeutics | 40 |
Forian | 37 |
BeyondSpring | 36 |
SLS News
- 11 days ago - SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - GlobeNewsWire
- 12 days ago - SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML - GlobeNewsWire
- 24 days ago - SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers - GlobeNewsWire
- 5 weeks ago - SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS) - Business Wire
- 6 weeks ago - SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 - GlobeNewsWire
- 2 months ago - SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire